Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA) announced that its CEO, Sean P. Bohen, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 1:30 p.m. ET. A live webcast of the event will be available on Olema's website, where it will be archived for 14 days.

Olema is focused on developing targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in clinical trials for treating ER-positive, HER2-negative breast cancer.

SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42^nd Annual Growth Conference on Thursday, August 11, 2022 at 1:30 p.m. ET.

A live webcast of the fireside chat and the corporate presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.

About Olema Oncology 
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

FAQ

What is the date and time of Olema Pharmaceuticals' participation in the Canaccord Genuity conference?

Olema Pharmaceuticals will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 1:30 p.m. ET.

Where can I watch the Olema Pharmaceuticals fireside chat?

The Olema Pharmaceuticals fireside chat will be available via a live webcast on the company's website and archived for 14 days.

What is Olema Pharmaceuticals' lead product candidate?

Olema Pharmaceuticals' lead product candidate is OP-1250, a therapy for women's cancers.

What types of cancer is Olema Oncology targeting with its therapies?

Olema Oncology focuses on developing therapies for women's cancers, including ER-positive, HER2-negative breast cancer.

What is the significance of OP-1250 in Olema's clinical trials?

OP-1250 is being evaluated as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader in clinical trials.